<DOC>
	<DOC>NCT00127140</DOC>
	<brief_summary>The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral vorinostat in patients with malignant lymphoma.</brief_summary>
	<brief_title>A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patients who relapsed after complete or partial response, or ineffective in previous chemotherapy Patients with history of chemotherapy, antibody therapy, radiotherapy, during the previous 4 weeks (6 months for radioisotopelabeled antibody) Any uncontrolled concomitant illness Are pregnant or breastfeeding Serious drug or food allergy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>